Hooper u make AF look like an elementary school kid. I am sure he really really hate to see your rebuttals. Go get them Doc. You have an exceptional talent of research with short amount of time. Have you thought about your own blog may be bio companies or similar? You add so much value to the MB and help dispel the non-sense and lies.
I may have confused AF's treatment of 2-73 with 3-71 in this statement from a previous post:
AF cried foul about the presenting of A2-73 epilepsy preclinical findings again, and some here were questioning it.
As it relates to your statement:
"Continuing, Feuerstein chides Anavex's recent announcement regarding 3-71, labeling it a "repeat." No, it's not a repeat. A repeat would be a press release citing the same 2014 results, which were based on a poster presentation at the AAIC [6]. The new results that were announced recently, which were deemed fit to publish in a major, peer reviewed scientific journal, were just that-new results. Yes, the same compound is the topic, but it included remarkable, new data, including the observation of reversal of synaptic loss in hippocampal neurons [7, 8]."
How is the use of AF710B vs 3-71 determined? Is it normal for the scientist to continue using his naming after the compound is bought and renamed by the company? I have always thought when I saw it as AF710B that that was work that was done before Anavex acquired it, in March 2012 I believe. Can you shed any light on that and/or determine when this newer study was done? §AVXL